



COPY OF PAPERS
ORIGINALLY FILED

EE652176582US

USA

PATENT

Attorney's Docket No. B-4275PCT 618999-1

COMBINED DECLARATION AND POWER OF ATTORNEY
(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL, CONTINUATION, OR CIP)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type: (check one applicable item below)

- original
 design
 supplemental

NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

- national stage of PCT

NOTE: If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION, OR CIP.

- divisional
 continuation
 continuation-in-part (CIP)

INVENTORSHIP IDENTIFICATION

WARNING: If the inventors are each not the inventors of all the claims an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

PHARMACOLOGICALLY ACTIVE POLYPEPTIDE GLYCOCOCONJUGATES

SPECIFICATION IDENTIFICATION

the specification of which: (complete (a), (b) or (c))

- (a) is attached hereto.
(b) was filed on _____ as Serial No. 0 / _____
or Express Mail No., as Serial No. not yet known, _____
and was amended on _____ (if applicable).

NOTE: Amendments filed after the original papers are deposited with the PTO which contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67.

- (c) was described and claimed in PCT International Application No. ES99/00338
filed on October 21, 1999 as amended under PCT Article 19 (1)
on _____ (if any).



ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code Federal Regulations § 1.56.

[] In compliance with this duty there is attached an information disclosure statement 37 CFR 1.97.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign applications(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) [] no such applications have been filed.
(e) such applications have been filed as follows.

NOTE: Where item (c) is entered above and the International Application which designated the U.S. claimed priority check item (e), enter the details below and make the priority claim.

**EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN(S)) PRIOR TO THIS U.S. APPLICATION**

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
SPAIN	P9900408	26 02 99	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

**ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN(S)) PRIOR TO THIS U.S. APPLICATION**





COPY OF PAPERS
ORIGINALLY FILED

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Richard P. Berg, Reg. No. 28,145 Victor Replikin, Reg. No. 45,039
Mavis S. Gallenson, Reg. No. 32,464 John Palmer, Reg. No. 36,885
Kam C. Louie, Reg. No. 33,008 Peter D. Galloway, Reg. No. 27,885
Ross A. Schmitt, Reg. No. 42,529 William R. Evans, Reg. No. 25,858

(check the following item, if applicable)

[] Attached as part of this declaration and power of attorney is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s).

SEND CORRESPONDENCE TO:

Richard P. Berg, Esq.
c/o LADAS & PARRY
5670 Wilshire Boulevard, Suite 2100
Los Angeles, California 90036-5679

DIRECT TELEPHONE CALLS TO:
(Name and telephone number)

Richard P. Berg
(323) 934-2300

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Full name of sole or first inventor AURORA BRIEVA DELGADO

Inventor's signature Aurora Brieva

Date July 9, 2001

Country of Citizenship

Spain

Residence Josefa Valcarcel 12. Chalet 10. 28027 MADRID, Spain.

Post Office Address the same

Full name of second joint inventor, if any VICENTE GARCIA VILLARRUBIA

Inventor's signature Vicente Garcia

Date July 9, 2001

Country of Citizenship

Spain

Residence Cornisa 11. Residencial La Cornisa. Bloque G 1º A. 28230 LAS ROZAS (Madrid), Spain.

Post Office Address the same

Full name of third joint inventor, if any ANTONIO GUERRERO GOMEZ-PALEO

Inventor's signature Antonio Guerrero

Date July 9, 2001

Country of Citizenship


Spain

Residence Plaza Reyes Lagos 13 - 9º D. 28007 MADRID, Spain.

Post Office Address the same



Full name of **fourth joint inventor**, if any JUAN PABLO PUJOL RANTERT


Inventor's signature 

Date July 9, 2001 Country of Citizenship Spain

Residence Antonio Arias 12 - 6º A. 28009 MADRID, Spain.

Post Office Address the same

Full name of **fifth joint inventor**, if any GUILLERMO GIMENEZ GALLEGOS

Inventor's signature 

Date July 9, 2001 Country of Citizenship Spain

Residence Pablo Aranda 3. 28006 MADRID, Spain.

Post Office Address the same

Full name of **sixth joint inventor**, if any JOSE ANTONIO MATJI TUDURI

Inventor's signature 

Date July 9, 2001 Country of Citizenship Spain

Residence Serranagna 8. 28043 MADRID, Spain.

Post Office Address the same





CO~~PI~~ OF PAPERS
ORIGINALLY FILED


CHECK PROPER BOX(ES) FOR ANY OF THE FOLLOWING ADDED PAGES(S)
WHICH FORM A PART OF THIS DECLARATION

- Signature for third and subsequent joint inventors. *Number of pages added* 1
- Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor.
Number of pages added _____
- Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47.
Number of pages added _____
- ***
- Added pages to combined declaration and power of attorney for divisional, continuation-in-part (CIP) application.
Number of pages added _____
- ***
- Authorization of attorney(s) to accept and follow instructions from representative.

If no further pages form a part of this Declaration then end this Declaration with this page and check the following item.

- This declaration ends with this page.





COPY OF PAPERS
ORIGINALLY FILED

EL652176582US

1

PHARMACOLOGICALLY ACTIVE POLYPEPTIDE GLYCOCONJUGATES
SPECIFICATION

The growing awareness with regard to the mechanisms of function and regulation of the immunological system have raised, in the last years, the possibility of 5 therapeutically modulating its function.

The great diversity of substances of different origin, natural and synthetic, capable of modulating some immunological mechanisms is due partly to the enormous possibility of recognizing substances which are foreign 10 to the organism that is its own. In (GH Werner, P Follés " Immunostimulating agents : what next?. A review of their present and potential medical applications." Eur. J. Biochem 242, 1-19 (1996)) some of the products of recent development are described, as well as their 15 possible therapeutical implications.

From among the various endogenous mediators there is one which raises one of the most important therapeutical challenges, it is the tumor necrosis factor (TNF). This molecule shows some special distinct characteristics (R 20 Ksontini, SLD MacKay, LL Moldawer " Revisiting the role of tumor necrosis factor α and the response to surgical injury and inflammation" Arch. Surg. 133, 558-567 (1998). JL Alonso " La compleja fisiología del factor de necrosis tumoral." Inmunología 8, (3) 73-94 (1989). T. 25 Calandra " Importance des cytokines dans les syndromes septiques." Med. Hyg. 49, 609-614 (1991). A Eigler, B. Sinha, G Hartman, S Endres " Taming TNF: strategies to restrain this pro inflammatory cytokines." Immunology Today 18, 487-492 (1997). R González-Amaro, C García- 30 Monzón, L. García-Buey, R Moreno-Otero, JL Alonso, E Yagüe, JP Pivel, M López-Cabrera, E Fernández-Ruiz, F Sánchez-Madrid " Induction of Tumor Necrosis Factor α Production by Human Hepatocytes in Chronic viral Hepatitis." J.Exp. Med 179, 841-848 (1994).): 35 The tumor necrosis factor (TNF) is a pleiotropic